Aicardi-Goutieres Syndrome (AGS) care technology platforms are the digital infrastructure underpinning modern management of Aicardi-Goutieres Syndrome — a rare, severe, progressive inflammatory encephalopathy and prototypic type I interferonopathy caused by mutations in genes encoding nucleic acid metabolism and innate immune sensing enzymes, including TREX1 (encoding the 3'-5' DNA exonuclease TREX1, responsible for AGS1 — the most severe subtype, often presenting perinatally with a congenital TORCH-like syndrome, severe cerebral calcifications, and progressive leukodystrophy), RNASEH2B, RNASEH2A, and RNASEH2C (encoding the three subunits of the trimeric RNase H2 ribonuclease complex required for removal of ribonucleotides mis-incorporated into genomic DNA during replication, with RNASEH2B mutations producing AGS2 — the most common and comparatively milder subtype, RNASEH2A producing AGS3, and RNASEH2C producing AGS4), SAMHD1 (encoding the dNTP triphosphohydrolase and nuclease SAMHD1 required for restriction of HIV-1 and regulation of reverse-transcription-associated nucleic acid sensing, responsible for AGS5), ADAR1 (encoding the adenosine deaminase acting on RNA enzyme ADAR1 required for A-to-I editing of double-stranded RNA to prevent activation of MDA5/IFIH1-mediated innate immune sensing of endogenous dsRNA, responsible for AGS6), and IFIH1 (encoding MDA5, the cytosolic dsRNA innate immune sensor whose gain-of-function mutations cause constitutive type I interferon pathway activation, responsible for AGS7) — all converging on defective clearance or inappropriate sensing of endogenous nucleic acid species that activate the cGAS-STING or MDA5-MAVS-IRF3/IRF7 innate immune pathway to produce a constitutive, self-sustaining type I interferon signature (measurable as elevated cerebrospinal fluid interferon-alpha, elevated serum interferon-alpha by ELISA or interferon gene score by transcriptomics, and a peripheral blood interferon-stimulated gene expression signature) that drives cerebrovascular inflammation with intracranial calcifications (typically in the basal ganglia, thalami, and periventricular white matter on brain CT), progressive cerebral white matter injury producing a leukodystrophy on MRI, cortical atrophy, cerebral microangiopathy, and the clinical syndrome of spastic quadriplegia or diplegia, progressive microcephaly, epilepsy, severe intellectual disability, loss of developmental milestones in early childhood, and in severe TREX1-associated AGS1, a neonatal-onset hepatosplenomegaly, thrombocytopenia, transaminase elevation, and consumptive coagulopathy resembling congenital viral infection — integrating interferon signature monitoring platforms, neurological deterioration surveillance systems, JAK inhibitor therapy management platforms (baricitinib, ruxolitinib, tofacitinib — now increasingly used as disease-modifying therapy targeting the JAK1/TYK2 and JAK1/JAK2 signaling kinases downstream of type I and type II interferon receptors to reduce the ISG score and slow neurological progression), epilepsy management and seizure frequency monitoring platforms, developmental surveillance and rehabilitation coordination systems, cardiological monitoring platforms (for AGS-associated cardiomyopathy and vascular inflammation), hematological monitoring systems (for AGS1 neonatal thrombocytopenia and coagulopathy), and multidisciplinary neurology-immunology-rehabilitation coordination tools that enable pediatric neurologists, pediatric immunologists, metabolic specialists, neuropsychologists, and rehabilitation specialists to detect interferon signature elevation requiring JAK inhibitor therapy initiation or escalation, epilepsy deterioration requiring anticonvulsant adjustment, neurological regression requiring urgent investigation, cardiomyopathy progression, and JAK inhibitor toxicity before they produce preventable disease acceleration, refractory epilepsy, or life-threatening complications. When an AGS care platform is unavailable or degraded, pediatric neurologists cannot access the interferon-stimulated gene score trajectories, CSF interferon-alpha levels, brain MRI leukodystrophy progression assessments, seizure frequency trends, developmental milestone regression documentation, JAK inhibitor dose escalation histories, complete blood count monitoring results, lipid panel surveillance data, and cardiac echo assessments that guide treatment decisions — and the longitudinal clinical monitoring that distinguishes stable AGS neurological status from progressive leukodystrophy requiring JAK inhibitor escalation or urgent neurological intervention collapses.
This guide covers what Aicardi-Goutieres Syndrome care technology platforms need to monitor, why continuous availability matters across the spectrum of AGS disease manifestations — interferon signature-driven neurological injury, progressive leukodystrophy, epilepsy, JAK inhibitor-associated immunosuppression, and cardiological complications — and how to build a monitoring strategy that protects interferon signature surveillance, JAK inhibitor therapy management, epilepsy monitoring, developmental regression detection, and the subtype-specific clinical risk management workflows that AGS care requires.
Why AGS Care Tech Platforms Cannot Afford Downtime
AGS management requires continuous interferon signature monitoring across the entire treatment course: interferon-stimulated gene (ISG) score measurement from peripheral blood transcriptomics every 3-6 months provides the primary biomarker of disease activity and JAK inhibitor treatment response; CSF interferon-alpha levels at baseline and when disease activity is in question provide direct measurement of central nervous system interferon production; brain MRI with detailed white matter volumetric analysis, T2 FLAIR leukodystrophy quantification, and diffusion-weighted imaging every 6-12 months tracks leukodystrophy progression or stabilization under JAK inhibitor therapy; serial brain CT provides calcification burden assessment; serial seizure frequency monitoring using parental diary platforms and EEG surveillance drives anticonvulsant optimization; serial neurological assessments with standardized developmental milestone tracking quantify treatment-related stabilization or disease progression; JAK inhibitor therapy requires CBC with differential for lymphopenia and neutropenia, comprehensive metabolic panel for hepatotoxicity, lipid panel for dyslipidemia (a known adverse effect of JAK inhibitors), and immunological monitoring for opportunistic infection risk in patients receiving ongoing immunosuppression. The platforms that support AGS programs must remain continuously available — because an AGS patient whose ISG score surveillance lapsed during a platform failure may have crossed the threshold for JAK inhibitor dose escalation undetected, or whose leukodystrophy progression was not captured on scheduled MRI due to coordination platform failures, represents a preventable risk of unchecked neurological deterioration.
Interferon signature monitoring is the primary biomarker-driven treatment decision platform for AGS. The ISG score — derived from quantitative PCR or transcriptomic measurement of a validated panel of interferon-stimulated genes (IFIT1, IFIT2, IFIT3, MX1, RSAD2, IFI27, ISG15, HERC5, and related genes) — is the most sensitive and accessible measure of type I interferon pathway activation in AGS; an elevated ISG score (typically defined as >2 standard deviations above the mean of healthy controls) at baseline establishes active interferonopathy; serial ISG scores under JAK inhibitor therapy assess treatment response, with normalized or substantially reduced ISG scores indicating effective JAK-STAT pathway suppression; ISG score elevation during JAK inhibitor therapy indicates inadequate dose, treatment failure, or drug discontinuation; JAK inhibitor dose escalation, switching, or combination therapy decisions are driven by ISG score trajectory; platforms that integrate serial ISG score data, flag threshold-crossing values, and compare current values against individual baseline and treatment-period trajectories provide the interferon monitoring infrastructure that drives disease-modifying treatment decisions in AGS.
Neurological deterioration detection requires continuous platform availability across MRI, EEG, and developmental surveillance. AGS neurological injury from the constitutive interferon signature is progressive in untreated patients and partially arrested under JAK inhibitor therapy in a substantial proportion; detecting deterioration requires integration of serial MRI leukodystrophy quantification with established baseline (brain MRI white matter signal abnormalities on T2/FLAIR, white matter volume loss, callosal thinning, cystic periventricular leukomalacia-like changes, calcification progression on CT), serial developmental milestone documentation comparing current status against expected trajectory under treatment, serial EEG for epileptiform activity burden and subclinical seizure detection, serial head circumference measurements for microcephaly progression, and clinical severity scoring on validated AGS scales; platform failures that prevent MRI result integration, EEG report access, developmental assessment scheduling, or neurological assessment scoring disrupt the longitudinal surveillance that distinguishes JAK inhibitor treatment success from disease progression requiring therapeutic escalation.
JAK inhibitor safety monitoring requires real-time laboratory surveillance. Baricitinib, ruxolitinib, and tofacitinib — the JAK inhibitors used in AGS — produce class-effect adverse effects that require systematic monitoring: CBC for lymphopenia (absolute lymphocyte count <500/µL requiring dose reduction or interruption), neutropenia (ANC <1000/µL requiring dose adjustment), and anemia; comprehensive metabolic panel for hepatocellular liver enzyme elevation and creatinine; lipid panel for LDL cholesterol elevation requiring statin initiation; reactivation surveillance for latent tuberculosis (IGRA testing before JAK inhibitor initiation), varicella-zoster (VZV serology with vaccination before starting when feasible), herpes simplex, and CMV in immunosuppressed patients; infection surveillance for bacterial and opportunistic infections in patients receiving chronic JAK inhibitor-mediated immunosuppression; platform failures that prevent CBC or LFT result access delay dose adjustment decisions that prevent JAK inhibitor-associated cytopenias, hepatotoxicity, and opportunistic infections.
What to Monitor on an AGS Care Tech Platform
Interferon Signature and Biomarker Monitoring Platform
The interferon signature and biomarker monitoring service — integrating ISG score measurements from peripheral blood transcriptomics with trend analysis and treatment-response threshold alerts, CSF interferon-alpha level result feeds with comparison against laboratory reference ranges and individual baseline values, CXCL10/IP-10 serum level tracking as an accessible surrogate interferon activity biomarker, complement level monitoring for AGS-associated lupus-like systemic inflammatory features (particularly in TREX1-AGS1 and SAMHD1-AGS5), anti-dsDNA and ANA antibody surveillance for lupus-like systemic features, serial ISG score trending under JAK inhibitor therapy with treatment-response classification (responder, partial responder, non-responder), inter-current ISG score elevation alerts indicating JAK inhibitor treatment failure, and biomarker-guided dose escalation recommendation generation — is the highest-priority monitoring target for the AGS care platform. Check at a 1-minute interval with immediate escalation. Interferon signature surges may indicate JAK inhibitor failure, dose reduction-related rebound, or inter-current illness-triggered flares; normalized ISG scores under treatment provide reassurance of mechanistic treatment effect; platform failures that prevent ISG score result access or inter-current ISG elevation alerts delay the JAK inhibitor dose escalation decisions that slow neurological progression in AGS.
Neurological Surveillance and Leukodystrophy Monitoring Platform
Monitor the neurological surveillance service — including brain MRI scheduling with leukodystrophy quantification result integration (T2 FLAIR white matter signal abnormality volume, callosal cross-sectional area, white matter volume comparisons against age-matched references), brain CT calcification burden scoring, MRI diffusion-weighted imaging acute injury alert generation, EEG result integration with epileptiform activity scoring, serial developmental milestone assessment scheduling with regression detection alerts (loss of previously acquired milestones triggering urgent neurological review), head circumference measurement tracking for microcephaly progression, serial neurological examination scoring on validated AGS severity scales, neuroimaging surveillance schedule adherence monitoring, and urgent MRI scheduling trigger generation when neurological regression is detected — at a 1-minute interval. MRI leukodystrophy progression under JAK inhibitor therapy is the primary radiological treatment-response endpoint; acute MRI DWI changes may indicate inter-current inflammatory injury requiring urgent evaluation; developmental milestone regression in a previously stable AGS patient on JAK inhibitors requires immediate ISG score measurement and neurological review; platform failures that prevent MRI result integration, developmental milestone regression detection, or EEG access delay the most urgent therapeutic decisions in AGS management.
JAK Inhibitor Therapy Management Platform
Monitor the JAK inhibitor therapy management service — including baricitinib, ruxolitinib, or tofacitinib prescription dose tracking with weight-based dose adjustment calculation for pediatric patients, CBC with differential result feeds with lymphopenia and neutropenia threshold alerts (ANC <1000/µL for dose reduction, ANC <500/µL for interruption; ALC <500/µL for dose reduction), LFT result feeds with hepatotoxicity threshold alerts (ALT/AST >3× ULN requiring dose reduction or interruption, >5× ULN requiring interruption), lipid panel monitoring with LDL elevation alerts and statin initiation recommendations, drug adherence tracking with missed-dose pattern identification, drug-drug interaction flagging (particularly with QT-prolonging co-medications and strong CYP3A4 inhibitors affecting ruxolitinib and tofacitinib metabolism), JAK inhibitor trough level tracking where pharmacokinetic monitoring is performed, switching protocol coordination when treatment failure is identified, and JAK inhibitor restart coordination after treatment interruptions for infections or surgery — at a 1-minute interval. JAK inhibitor dosing in pediatric AGS requires weight-based adjustments as children grow; laboratory-based dose adjustments for cytopenias and hepatotoxicity require prompt CBC and LFT access; platform failures that prevent laboratory result access or dose adjustment documentation create avoidable JAK inhibitor toxicity and treatment interruption risks.
Epilepsy Management and Seizure Surveillance Platform
Monitor the epilepsy management service — including seizure diary data integration from caregiver-recorded seizure frequency logs, anticonvulsant prescription tracking with pediatric weight-based dose management, EEG scheduling and result integration with epileptiform discharge burden scoring and subclinical status epilepticus detection, anticonvulsant blood level monitoring for phenobarbital, phenytoin, valproate, and other agents where therapeutic drug monitoring is indicated, seizure cluster and status epilepticus threshold alert generation requiring urgent ED escalation, rescue medication protocol (buccal midazolam, rectal diazepam) distribution and documentation, anticonvulsant adverse effect monitoring, inter-current illness seizure frequency escalation tracking, and neurologist review scheduling triggers when seizure frequency exceeds threshold — at a 1-minute interval. AGS-associated epilepsy is often refractory and driven by ongoing interferon-mediated neuro-inflammation; seizure cluster detection and status epilepticus prevention require continuous seizure frequency monitoring; platform failures that prevent seizure diary data access or anticonvulsant blood level review delay the dose adjustments that prevent refractory status epilepticus in AGS.
Cardiology and Systemic Monitoring Platform
Monitor the cardiology and systemic inflammatory monitoring service — including echocardiography scheduling for AGS-associated cardiomyopathy and pericarditis surveillance, ECG monitoring for JAK inhibitor-associated QT prolongation risk, cardiac enzyme monitoring when cardiomyopathy is suspected, lupus-like systemic inflammatory feature monitoring (joint swelling, skin rash, serositis) in TREX1-AGS1 and SAMHD1-AGS5 patients, skin vasculitic lesion documentation and dermatology coordination, hepatosplenomegaly assessment scheduling, thyroid function monitoring (hypothyroidism reported in some AGS patients), and glaucoma surveillance for ocular hypertension associated with AGS — at a 2-minute interval. AGS-associated cardiomyopathy and vasculopathy from type I interferon-driven vascular inflammation can produce significant morbidity; systemic lupus-like features in TREX1-AGS and SAMHD1-AGS require systemic monitoring beyond the neurological focus; platform failures that prevent echo scheduling or cardiac enzyme access delay cardiomyopathy detection in a population where cardiac complications may be under-recognized.
Infection Surveillance and Immunosuppression Safety Platform
Monitor the infection surveillance service — including opportunistic infection symptom reporting and triage, VZV reactivation surveillance with antiviral prophylaxis management, CMV and EBV surveillance in patients receiving long-term JAK inhibitor immunosuppression, bacterial infection threshold alert generation (fever protocols for immunosuppressed patients), tuberculosis surveillance with annual IGRA testing, hepatitis B reactivation monitoring where applicable, vaccination status tracking (live vaccines generally contraindicated during JAK inhibitor therapy; recommended catch-up schedules for non-live vaccines before JAK inhibitor initiation), and JAK inhibitor dose adjustment and temporary interruption coordination when infection is diagnosed — at a 2-minute interval. JAK inhibitors suppress adaptive and innate immune signaling, increasing infection risk; VZV reactivation (shingles) is the most common serious infection in adult JAK inhibitor recipients; herpes simplex, CMV, and bacterial infections require vigilant surveillance; platform failures that prevent infection surveillance or antiviral prophylaxis management create avoidable infection risk in immunosuppressed AGS patients.
Telemedicine and Multidisciplinary Coordination Platform
Monitor the telemedicine session API, pediatric neurology consultation scheduling, immunology coordination, rehabilitation therapy scheduling (physiotherapy, occupational therapy, speech and language therapy, augmentative and alternative communication systems), neuropsychological testing coordination, palliative care coordination, gastrostomy and nutritional support management, and family caregiver support program coordination at a 2-minute interval. AGS management requires continuous coordination across pediatric neurology, immunology, rehabilitation medicine, neuropsychology, cardiology, and palliative care; platform failures interrupt the multidisciplinary consultation that manages overlapping neurological surveillance, JAK inhibitor therapy, epilepsy management, and rehabilitation domains.
EHR Integration Endpoint
Monitor the EHR synchronization service at a 5-minute interval. AGS patients presenting for emergency neurological assessment require rapid provider access to their current JAK inhibitor regimen, ISG score trajectory, seizure frequency trend, current anticonvulsant regimen with blood levels, brain MRI leukodystrophy baseline, AGS genetic subtype, and emergency seizure protocol documentation.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock pediatric neurologists, immunologists, and AGS care coordinators out of interferon signature monitoring platforms, neurological surveillance systems, JAK inhibitor therapy management tools, and epilepsy management dashboards simultaneously — disabling the entire AGS multisystem digital management infrastructure.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance across all patient-facing, clinician-facing, and integration domains.
Alerting Strategy for AGS Care Tech Platforms
Immediate clinical escalation (24/7): Interferon signature and biomarker monitoring, neurological surveillance and leukodystrophy monitoring, JAK inhibitor therapy management, epilepsy management and seizure surveillance, authentication service. These affect real-time AGS disease activity detection, neurological deterioration alerts, JAK inhibitor toxicity prevention, and seizure cluster early warning that cannot tolerate delayed detection.
Immediate clinical operations escalation: Infection surveillance and immunosuppression safety. Failures affect opportunistic infection detection in immunosuppressed AGS patients receiving JAK inhibitor therapy.
High-priority immediate escalation: Cardiology and systemic monitoring, telemedicine and multidisciplinary coordination. Access failures interrupt cardiomyopathy surveillance and the specialist coordination that manages AGS's neurological, immunological, and rehabilitation domains.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour.
Advance warning: SSL certificate expiry, 30 days in advance, across all patient-facing and integration domains.
Interferon signature and neurological surveillance require 24/7 alerting because AGS inflammatory flares — inter-current illness-triggered ISG score surges, breakthrough seizures, and acute neurological regression events — can develop rapidly at any time; ISG elevation alerts, developmental regression detection, and status epilepticus threshold alerts require immediate response regardless of time of day because the window for therapeutic escalation is narrow and irreversible neurological injury accumulates during untreated inflammatory flares.
Status Page as a Clinical Safety Signal
AGS program nurses and on-call pediatric neurologists managing after-hours contacts from families reporting new seizures, fever in an immunosuppressed JAK inhibitor patient, acute developmental regression, or new neurological symptoms need immediate platform status awareness before initiating escalation protocols. A published status page allows on-call coordinators to distinguish a platform incident from connectivity problems — and to initiate phone-based triage, emergency seizure management guidance, fever protocol activation for immunosuppressed patients, and urgent hospital escalation when the digital platform is confirmed unavailable.
For AGS programs coordinating interferon signature monitoring, neurological surveillance, JAK inhibitor management, epilepsy monitoring, and cardiology surveillance across geographically dispersed pediatric and adult patients — a status page enables rapid identification of platform failures and activation of manual emergency protocols. Publish the status page URL in care coordinator workstations, on-call neurology and immunology systems, and family caregiver emergency protocol documents.
The Business Case: Neurological Preservation, JAK Inhibitor Safety, and AGS Program Quality
AGS specialty programs face significant cost exposure from preventable neurological deterioration in patients whose ISG score surveillance lapsed during platform failures delaying JAK inhibitor dose escalation, JAK inhibitor toxicity events from delayed CBC or LFT result access causing undetected cytopenias and hepatotoxicity, status epilepticus events from lapsed seizure frequency monitoring preventing timely anticonvulsant adjustment, opportunistic infections from missed infection surveillance in patients receiving long-term immunosuppression, cardiomyopathy diagnosis delays from lapsed echocardiography scheduling, and developmental regression from unchecked inflammatory activity during interferon monitoring platform failures. Platform reliability that supports continuous interferon signature monitoring, JAK inhibitor safety surveillance, epilepsy management, and neurological deterioration detection is upstream of the most preventable and costly outcomes in AGS.
AGS program quality metrics increasingly include time-to-ISG-normalization from JAK inhibitor initiation, MRI leukodystrophy stabilization rates under treatment, seizure-free days under optimized anticonvulsant management, JAK inhibitor adverse effect detection lead time from laboratory threshold crossing, and developmental regression detection time from milestone loss event. Platform reliability directly determines whether these quality metrics are achievable or whether surveillance gaps allow the outcomes they measure to occur.
External monitoring from Vigilmon provides the documented, independent availability record that AGS program directors can present to hospital administration, rare disease payer medical directors, and research funding bodies as evidence that the program's digital infrastructure supports the level of continuous interferon signature monitoring, neurological surveillance, and JAK inhibitor safety monitoring that Aicardi-Goutieres Syndrome care requires.
Vigilmon Setup for AGS Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Interferon signature and biomarker monitoring | 1 min | PagerDuty (immediate, 24/7) | | Neurological surveillance and leukodystrophy monitoring | 1 min | PagerDuty (immediate, 24/7) | | JAK inhibitor therapy management | 1 min | PagerDuty (immediate, 24/7) | | Epilepsy management and seizure surveillance | 1 min | PagerDuty (immediate, 24/7) | | Auth service | 1 min | PagerDuty (immediate) | | Infection surveillance and immunosuppression safety | 2 min | PagerDuty (immediate) | | Cardiology and systemic monitoring | 2 min | PagerDuty + Slack (immediate) | | Telemedicine and multidisciplinary coordination | 2 min | PagerDuty + Slack (immediate) | | EHR synchronization endpoint | 5 min | Slack (business hours) | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the interferon signature and biomarker monitoring platform at a 1-minute interval with 24/7 PagerDuty alerting
- Add neurological surveillance and leukodystrophy monitoring at a 1-minute interval with immediate 24/7 escalation
- Add JAK inhibitor therapy management at a 1-minute interval with immediate alerting
- Add epilepsy management and seizure surveillance at a 1-minute interval with immediate alerting
- Add infection surveillance and immunosuppression safety at a 2-minute interval with immediate alerting
- Add cardiology and systemic monitoring at a 2-minute interval with immediate alerting
- Add telemedicine and multidisciplinary coordination with immediate alerting
- Add authentication and EHR synchronization
- Enable SSL monitoring across all patient-facing and integration domains
- Publish the automatic status page URL in care coordinator workstations, on-call neurology and immunology systems, and family caregiver emergency protocol documents
Conclusion
AGS care tech platforms hold the clinical surveillance infrastructure that makes Aicardi-Goutieres Syndrome manageable across its complex neurological and immunological involvement — interferon signature monitoring platforms, JAK inhibitor therapy management systems, neurological deterioration surveillance dashboards, epilepsy management tools, infection surveillance platforms, and cardiological monitoring dashboards that cannot undo the preventable leukodystrophy progression, status epilepticus events, JAK inhibitor toxicity episodes, opportunistic infections, and developmental regression accumulated during periods of unmonitored ISG score elevation, absent JAK inhibitor laboratory surveillance, and inaccessible neurological assessment coordination. Their availability is a prerequisite for interferon pathway activity detection, JAK inhibitor dose optimization, leukodystrophy progression monitoring, seizure frequency surveillance, opportunistic infection prevention, cardiomyopathy detection, and the specialist access that patients with AGS depend on across a lifelong progressive neurological illness that — while presenting in infancy with a devastating TORCH-like encephalopathy in severe TREX1-AGS1, or with a subacute developmental regression in RNASEH2B-AGS2 — requires sustained JAK inhibitor therapy, systematic biomarker monitoring, and continuous epilepsy surveillance to prevent the unchecked interferon-driven neurological injury that defines preventable deterioration in inadequately monitored AGS patients. When interferon signature monitoring platforms go offline, JAK inhibitor management systems fail, or neurological surveillance coordination platforms are unavailable, the clinical consequences extend to a disease where the difference between adequate and inadequate monitoring is measured in the ISG score elevation that persisted undetected until JAK inhibitor dose was escalated, the leukodystrophy volume added while MRI surveillance was disrupted, and the status epilepticus events that occurred because seizure frequency threshold alerts were not generated.
External monitoring from Vigilmon provides the independent, outside-in availability view that AGS program directors and health system IT teams need to catch failures before they affect interferon signature surveillance or neurological deterioration detection — with the documented incident record that accreditation bodies, rare disease registries, and payer audit teams accept as evidence of operational maturity.
Start monitoring your AGS care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #AGS #aicardiGoutieresSyndrome #interferonopathy #typeIinterferon #ISGscore #JAKinhibitor #baricitinib #ruxolitinib #leukodystrophy #TREX1 #RNASEH2 #SAMHD1 #ADAR1 #IFIH1 #cerebraCalcifications #epilepsy #microcephaly #cGASSTING #MDA5 #JAKSTATpathway #primaryimmunodeficiency #neurologicaldisease #pediatricneurology #immunology #healthtech #uptime #clinicaldocumentation #sre